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Objective To ‘map’ the current (2004) state of prenatal screening
in Europe.
Design (i) Survey of country policies and (ii) analysis of data from
EUROCAT (European Surveillance of Congenital Anomalies)
population-based congenital anomaly registers.
Setting Europe.
Population Survey of prenatal screening policies in 18 countries
and 1.13 million births in 12 countries in 2002–04.
Methods (i) Questionnaire on national screening policies and
termination of pregnancy for fetal anomaly (TOPFA) laws in 2004.
(ii) Analysis of data on prenatal detection and termination for
Down’s syndrome and neural tube defects (NTDs) using the
EUROCAT database.
Main outcome measures Existence of national prenatal screening
policies, legal gestation limit for TOPFA, prenatal detection and
termination rates for Down’s syndrome and NTD.
Results Ten of the 18 countries had a national country-wide policy
for Down’s syndrome screening and 14/18 for structural anomaly
scanning. Sixty-eight percent of Down’s syndrome cases (range
0–95%) were detected prenatally, of which 88% resulted in
termination of pregnancy. Eighty-eight percent (range 25–94%) of
cases of NTD were prenatally detected, of which 88% resulted in
termination. Countries with a first-trimester screening policy had
the highest proportion of prenatally diagnosed Down’s syndrome
cases. Countries with no official national Down’s syndrome
screening or structural anomaly scan policy had the lowest
proportion of prenatally diagnosed Down’s syndrome and NTD
cases. Six of the 18 countries had a legal gestational age limit for
TOPFA, and in two countries, termination of pregnancy was illegal
at any gestation.
Conclusions There are large differences in screening policies
between countries in Europe. These, as well as organisational and
cultural factors, are associated with wide country variation in
prenatal detection rates for Down’s syndrome and NTD.
Keywords Antenatal screening policy, Down’s syndrome,
neural tube defect, termination of pregnancy for fetal
anomaly.
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Over the past 20 years, there have been major advances in the
ﬁeld of prenatal screening for Down’s syndrome and in the
efﬁcacy of ultrasound scanning for the detection of fetal ano-
malies. Previously, older pregnant women were offered a diag-
nostic test (chorionic villus sampling [CVS] or amniocentesis,
both associated with a risk for causing miscarriage) to detect
Down’s syndrome. Offering an amniocentesis to the oldest
5% of women identiﬁed about 30% of pregnancies with
Down’s syndrome.1 Today, a number of different noninva-
sive screening tests, which can be offered to women of any
age, are available. These tests have different detection and
false-positive rates.2–4
Improved resolution of ultrasound scans and greater exper-
tise of operators have led to increased detection rates of fetal
structural anomalies at earlier gestations. A variety of national
policies or recommendations concerning prenatal screening
and diagnostic testing for Down’s syndrome and ultrasound
screening for structural anomalies have been developed in
different countries and areas within countries. One option
for parents following prenatal diagnosis of fetal anomaly is
termination of pregnancy. Termination of pregnancy is a con-
troversial subject in many countries, and the laws governing it
and legal gestation limits vary.
This study aims to ‘map’ the current (2004) state of pre-
natal screening and diagnosis in 18 countries in Europe that
are members of EUROCAT and to relate them to prenatal
detection and termination of pregnancy rates for speciﬁc
anomalies.
Methods
EUROCAT (European Surveillance of Congenital Anomalies)
is a network of population-based congenital anomaly registers
in Europe.5 Full member registries of EUROCAT send case
data on all congenital anomalies in their region, while asso-
ciate member registries send aggregate data only based on
pregnancy outcome and congenital anomaly subgroup. One
of the objectives of EUROCAT (which surveys more than 1.5
million births per year, including information on termination
of pregnancy for fetal anomaly [TOPFA] and covers 29% of
the annual European birth population) is to assess the impact
of prenatal screening.
A questionnaire was developed to explore current national
policies or recommendations in place in the year 2004 con-
cerning prenatal screening for congenital anomalies (Down’s
syndrome and structural anomalies) and the laws relating to
TOPFA.6 As well as determining the existence, or not, of an
ofﬁcial country-wide policy or recommendation, the ques-
tionnaire covered the tests actually offered throughout each
country. The questionnaire was ﬁlled in by a EUROCAT reg-
ister leader (clinician or public health professional) from each
participating country. Information about each participating
register is available on the EUROCAT website.5
Data on Down’s syndrome and neural tube defects (NTDs)
not associated with an abnormal karyotype were analysed.
Full EUROCAT member registries with information on ges-
tation at diagnosis known for at least 80% of cases, date of
delivery between 2002 and 2004 and data on termination of
pregnancy as well as on births were included in the data
analysis. Multiple pregnancies were excluded. Data on total
number of cases, prenatal detection and termination of preg-
nancy rates with median gestational age at prenatal diagnosis
were extracted from the EUROCAT central database.5 We
calculated the percentage of cases prenatally diagnosed and
the percentage of pregnancies resulting in termination with
95% binomial exact conﬁdence intervals.
For assessing the relation between the proportion of cases
with a prenatal diagnosis and country policies, we used risk
differences as the measure of association.7 For each policy
category, the risk difference represented the difference
between the overall proportion of cases with a prenatal diag-
nosis for countries with that policy and the overall proportion
of cases with a prenatal diagnosis for countries with the policy
category of reference. The same methodology was used to
assess risk differences in TOPFA.
For Down’s syndrome, the policy category of reference for
prenatal screening was ﬁrst or second-trimester screening for
the whole country; for NTD, the policy category of reference
was having a national policy in place for routine ultrasound.
For both malformations, the policy category of reference for
pregnancy termination was no legal gestational age limit. Ref-
erence categories were chosen so as to represent the most
frequent policy category. We used binomial regression,8
weighted by the number of cases for each country, to estimate
the risk differences with exact 95% CIs. Risk differences were
considered statistically signiﬁcant if the 95% CI did not
include zero.
Results
Eighteen questionnaires covering 18 countries were com-
pleted. The countries, their EUROCAT registers, total num-
ber of births in each country, and the number of births in
areas within the countries covered by the EUROCAT registers
in 2002 are shown in Table 1.
Table 2 shows the legal gestational age limit (if any) for
TOPFA in different countries.
Down’s syndrome
Table 3 outlines which countries had national screening
policies/recommendations for Down’s syndrome in place
in 2004, the maternal age ‘cutoff’ (if any) atwhich diagnostic
testing by CVS or amniocentesis is usually offered and the
type of screening offered (ﬁrst trimester—nuchal scan alone
Boyd et al.
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chemical screening).
Table 4 shows the total number of cases of Down’s syn-
drome (from the 12 full EUROCAT registries meeting the
inclusion criteria), percentage prenatally diagnosed, median
gestation at diagnosis and the number and percentage result-
ing in termination of pregnancy.
Of the 2308 cases of Down’s syndrome, 68% (95% CI 66–
70) were diagnosed prenatally at a median gestation of 17
weeks (range 10–40 weeks) and 1384 (60%, 95% CI 58–62)
of all affected pregnancies resulted in termination of preg-
nancy. If Malta and Ireland (where TOPFA is illegal) are
excluded from the analysis, of the 2154 cases of Down’s
syndrome, 73% (95% CI 71–74) of cases were prenatally
diagnosed at a median gestation of 16 weeks (range 10–40
weeks) and 64% (95% CI 62–66) of all affected pregnancies
resulted in TOPFA.
Thosetwocountries(DenmarkandSwitzerland)withapri-
marily ﬁrst-trimester screening policy had a proportion of
prenatally diagnosed cases 13% (95% CI 5–21) higher than
those countries with first- or second-trimester screening, the
reference group; those with no policy but some screening
(three countries: Croatia, Netherlands and Spain) had a pro-
portion of prenatally diagnosed cases 11% (95% CI 5–17)
lower than the reference group.
A Down’s syndrome case was 28% (95% CI 19–38) less
likely to result in termination of pregnancy in those countries
with a legal limit for nonlethal anomalies than those with no
legal gestational age limit for termination (the reference
group). Down’s syndrome cases from countries with a legal
gestation limit for termination of less than or equal to 28
weeks were 5% (95% CI 1–9) more likely to result in termi-
nation compared with the reference group.
Table 1. Eighteen countries with EUROCAT membership, total number of births in 2002, number and percentage of births covered by EUROCAT
registries
Countries EUROCATregister(s) Total births in
country in 2002**
Number (%) of births
in areas covered by
EUROCATregister(s)***
Austria Styria 72 900 10 500 (14)
Belgium Antwerp, Hainaut 113 300 29 500 (26)
Croatia Zagreb 43 000 5500 (13)
Denmark Odense 64 800 5100 (8)
England and Wales NorCAS, North West Thames, Oxford, Trent, Wessex, Wales 662 200 192 800 (29)
Finland Finland* 55 800*** 55 800 (100)
France Auvergne, Paris, Central East*, Strasbourg 773 500 159 400 (21)
Germany Mainz, Saxony-Anhalt 741 600 20 900 (3)
Ireland Cork and Kerry, Dublin 60 500*** 31 235 (52)
Italy Campania, Emilia Romagna, Northeast Italy, Tuscany 522 900 176 800 (34)
Malta Malta 3800*** 3800 (100)
Netherlands North Netherlands 209 300 20 400 (10)
Norway Medical Birth registry of Norway* 56 500*** 56 500 (100)
Portugal Southern Portugal 124 800 19 000 (15)
Poland Wielkopolska, Poland* 386 000 253 300 (66)
Spain Barcelona, Basque, Asturias, Madrid* 413 000 148 900 (36)
Sweden Sweden* 96 200*** 96 200 (100)
Switzerland Vaud 73 000 6800 (9)
*Associate member of EUROCAT.
**2002 World Population Data Sheet, Population Reference Bureau www.prb.org/pdf/WorldPopulationDS02_Eng.pdf.
***EUROCAT website: www.EUROCAT.ulster.ac.uk.
Table 2. National laws regarding TOPFA laws categorised by legal
gestational age limit
No legal
gestational
age limit
No legal
gestational age
limit if lethal
Legal gestational
age limit
•28 weeks
Not legal
at any
gestation
Austria Netherlands Finland Ireland
Belgium Norway Italy Malta
Croatia Portugal Poland*
England and
Wales
Denmark Spain
France Sweden
Germany Switzerland
*Only for severe malformations.
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Table 5 shows which countries had a national policy or
recommendation in place in 2004 for routine prenatal ultra-
sound scanning and the number and gestation at which the
scans are performed.
Fourteen of the 18 (78%) countries had a national policy or
recommendation regarding fetal ultrasound scanning in place
in 2004. These were for a speciﬁc anomaly scan at 18–23
weeks (Sweden 16–17 weeks, Finland 16–19 weeks) with, in
most countries, additional scans at 10–14 and 28–32 weeks.
There were no national scan policies in place in Ireland, Malta
or Spain, but anomaly scans were routinely offered. Routine
scans were not offered in the Netherlands.
Table 6 shows the total number and percentage of cases of
NTD (from full EUROCAT registry areas in each of the 12
countries providing data), percentage prenatally diagnosed,
median gestation at diagnosis and the number and percentage
resulting in termination of pregnancy. Of the 725 NTD cases,
88% (95% CI 86–90) were detected prenatally at a median
gestation of 17 weeks (range 8–40 weeks). Five hundred and
sixty out of 725 (77%, 95% CI 74–80) of all affected cases
were electively terminated. If Malta and Ireland (where
TOPFA is illegal) are excluded from the analysis, of the
669 NTD cases, 91% (95% CI 88–93) were prenatally diag-
nosed at a median gestation of 17 weeks (range 8–40 weeks)
and 84% (95% CI 81–86) of all affected pregnancies resulted
in TOPFA.
Those three countries (Ireland, Malta and Spain) with no
national ultrasound policy in place but where routine scans
were carried out had a proportion of prenatally diagnosed
NTD cases 17% (95% CI 9–25) lower than those countries
with a country-wide policy, the reference group. The one
country (Netherlands) with no policy and no routine scans
carried out had a proportion of prenatally diagnosed cases
14% (95% CI 6–33) lower than the reference group.
A NTD case was 45% (95% CI 26–64) less likely to result in
termination of pregnancy in those countries with a legal ges-
tation limit for nonlethal anomalies than those with no legal
gestational age limit for termination (the reference group).
NTD cases from countries with a legal gestation limit for
Table 3. National policies or recommendations for prenatal screening for Down’s syndrome in place in 2004 in 18 European countries
Countries National screening
policies or recommendations
for Down’s syndrome
screening test to be
offered to all women
First-trimester screening
actually offered
Second-trimester
biochemical
screening offered
Maternal age at
which CVS/amniocentesis
are offered
Nuchal
scan
Nuchal 1
biochemistry
Austria No 11 2 35
Belgium Yes 11 36 (charged if ,36)
Croatia No    35
Denmark Yes 21 2CVS/amniocentesis not offered
primarily on basis of maternal age
England and Wales Yes*  CVS/amniocentesis not offered
primarily on basis of maternal age
Finland Yes    39
France Yes 1  1 38
Germany Yes 1** 1** 1** 35
Ireland No 22 2 —
Italy Yes  1 35
Malta No 22 2 —
Netherlands No 22 1 ** 36
Norway No ** ** ** 38
Poland Yes 11 1 35
Portugal Yes 1   35
Spain No  ** ** 35
Sweden No  22 35
Switzerland Yes 21 *** CVS/amniocentesis not offered
primarily on basis of maternal age
1, in place in all areas of country; , in place in some areas within country.
*Screening policy was based on a detection rate, that is a screening test should be offered that had a detection rate for Down’s syndrome of
.60% for a false-positive rate of ,5%.
**May be private.
***Primarily ﬁrst-trimester screening, second-trimester screening for late bookers.
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–7 to +5) more likely to result in termination compared with
the reference group.
Discussion
This attempt to ‘map’ the state of prenatal diagnosis in 18
European countries in 2004 has conﬁrmed wide variation in
the availability and type of noninvasive screening tests for
Down’s syndrome, in the number of ultrasound scans offered
and in the legal gestational limits regarding TOPFA. This
broad view of prenatal diagnosis updates a previous report
describing prenatal diagnosis in different countries in Europe
between 1993 and 1995.9
In 2004, the majority of countries had moved from solely
offering older mothers a diagnostic test to having some form
of Down’s syndrome screening in place, with over half having
an ofﬁcial country-wide policy or recommendation for ﬁrst-
or second-trimester screening. Having a screening policy in
place had a measurable impact on prenatal detection rates for
Down’s syndrome; the registry areas in countries offering
primarily ﬁrst-trimester screening had a signiﬁcantly higher
detection rate than those using a mixed ﬁrst or second-
trimester screening policy; those with some screening but
no national screening policy in place were signiﬁcantly less
likely to detect a Down’s syndrome case prenatally. However,
there are wide variations in detection rates between different
countries using similar screening policies. For example, Ger-
many and France have both ﬁrst and second-trimester
screening policies; yet, the prenatal detection rate of Down’s
syndrome in the German registry area is 63% compared with
90%forFrance.Someofthisdifferencemaybeduetoahigher
proportion of older mothers in the French registry (Paris,
28% of mothers aged ‡35 years) than in the German registry
area (Mainz, 22% of mothers aged ‡35 years) in the period
2002–04. In all countries where TOPFA is legal, the majority
of cases of Down’s syndrome detected prenatally resulted in
termination of pregnancy; in most (7/10) registry areas, more
than 90% of prenatally diagnosed affected pregnancies re-
sulted in termination.
Most countries had an ofﬁcial, country-wide policy for
routine ultrasound anomaly scanning. This study has used
the prenatal detection of NTDs as an indicator for assessing
the efﬁcacy of ultrasound anomaly scanning because they are
relatively common and are associated with a high prenatal
detection rate.10 It may, however, be that other anomalies
which are more difﬁcult to detect prenatally would serve as
better indicators of the widespread use and quality of ultra-
sound anomaly screening. Those countries that did not have
a policy for offering routine scans had a signiﬁcantly lower
prenatal detection rate of NTD. One factor that may be
important when termination of pregnancy is being consid-
ered is the gestational age at suspicion of fetal anomaly. Of the
countries where TOPFA is legal, the country with the lowest
Table 4. Number of Down’s syndrome cases delivered in 2002–04, percentage prenatally diagnosed, median (range) weeks of gestation at
prenatal diagnosis and number and percentage resulting in termination of pregnancy in 19 EUROCAT registry areas in 12 countries
Countries Screening
policies*
Total cases of
Down’s syndrome
Prenatal diagnosis Termination of pregnancy
Number
of cases
% (95% CI)** Median gestation
(weeks) at
detection (range)
Number
of cases
% of prenatally
diagnosed
cases (95% CI)**
% of total
cases
(95% CI)**
Denmark A 22 14 64 (41–83) 11 (10–30) 12 86 (57–98) 55 (32–76)
Switzerland A 60 57 95 (86–99) 15 (10–35) 52 91 (81–97) 87 (75–94)
Belgium B 79 53 67 (56–77) 19 (12–25) 48 91 (79–97) 61 (49–72)
England and Wales B 652 429 66 (62–70) 17 (10–40) 325 76 (71–80) 50 (46–54)
France B 455 408 90 (87–92) 16 (11–35) 392 96 (94–98) 86 (83–89)
Germany B 36 23 63 (46–79) 15 (12–36) 22 96 (78–100) 61 (44–77)
Italy B 536 380 71 (67–75) 19 (10–40) 352 93 (90–95) 66 (62–70)
Croatia C 22 7 32 (14–55) 17 (17–17) 7 100 (59–100)*** 32 (14–55)
Netherlands C 88 37 42 (32–53) 14 (10–35) 27 73 (56–86) 31 (21–41)
Spain C 204 153 75 (68–81) 16 (11–29) 147 96 (92–99) 72 (65–78)
Ireland D 130 7 5 (2–11) 26 (13–35) 0 0 0
Malta D 24 0 — 0 0 — —
Total 2308 1568 68 (66–70) 17 (10–40) 1384 88 (87–90) 60 (58–62)
*A, ﬁrst-trimester screening offered in whole country; B, ﬁrst- or second-trimester screening offered in whole country; C, no national policy
but some form of screening in some of country; D, no screening.
**95% binomial exact conﬁdence intervals.
***One-sided 97.5 CI.
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was the Netherlands where the median gestation at prenatal
diagnosis was 31 weeks compared with 17 weeks for all coun-
tries. However, gestation at diagnosis is not the only factor; in
the German registry area, 90% of NTDs were prenatally
detected at a median gestation of 18 weeks and less than half
(44%) of the prenatally detected cases resulted in termination
of pregnancy, while in France, England and Wales and Spain,
there were high detection rates (94%) and high (92–98%)
termination rates.
Table 5. National policy/recommendations for routine prenatal ultrasound scans in place in 2004 in 18 European countries
Countries Routine ultrasound scan policy/recommendations Gestation at routine scans (weeks)
Austria Two scans 10–14*, 18–22, 30–34
Belgium Three scans 10–14, 18–23, 29–33
Croatia One scan 10–14*, 18–23, 34–37*
Denmark Two scans 10–14 (nuchal), 18
England and Wales Two scans 10–12, 18–23
Finland One or two scans 16–19 if only one scan, 13–14 and 18–20 if two scans
France Three scans 10–14, 18–23, 29–32
Germany Three scans 9–12, 19–22, 29–32
Ireland No national policy 18–22*
Italy Three scans 10–14, 18–23, 30
Malta No national policy 18–23*, 34–25*
Netherlands No national policy No routine scans
Norway One scan 18
Portugal Three scans 10–14, 18–23, 29–33
Poland Three scans 11–14,18–22, 28–32
Spain No national policy—practice varies between regions 10–14*, 18–23*, 29–33*
Sweden Two scans 10–14, 16–17
Switzerland Two scans 11–14, 20–22
*Not ofﬁcial policy but usually performed.
Table 6. Total number of cases of NTDs, percentage prenatally diagnosed, median (range) weeks of gestation at prenatal diagnosis and number
and percentage resulting in termination of pregnancy for 12 countries with EUROCAT registries
Countries Ultrasound
policies*
Total cases
of NTD
Prenatal diagnosis Termination of pregnancy
Number
of cases
% of total
cases
(95% CI)**
Median gestation
(weeks) at
detection (range)
Number
of cases
% of prenatally
diagnosed
cases (95% CI)**
% of total
cases
(95% CI)**
Belgium 1 23 19 83 (61–95) 16 (11–29) 17 89 (67–99) 74 (52–90)
Croatia 1 5 4 80 (28–100) 12 (8–16) 4 100 (40–100)*** 80 (28–100)***
Denmark 1 9 8 89 (52–100) 16 (12–36) 7 88 (47–100) 78 (40–97)
England and Wales 1 281 264 94 (91–96) 17 (10–40) 242 92 (88–95) 86 (82–90)
France 1 109 102 94 (87–97) 14 (10–32) 100 98 (93–100) 92 (85–96)
Germany 1 10 9 90 (56–100) 18 (11–34) 4 44 (14–79) 40 (12–74)
Italy 1 137 119 87 (80–92) 18 (10–39) 112 94 (88–98) 82 (74–88)
Switzerland 1 12 10 83 (52–98) 13 (12–18) 10 100 (69–100)*** 83 (52–98)
Ireland 2 48 27 56 (41–71) 22 (16–39) 0 0 (0–13)*** 0
Malta 2 8 2 25 (3–65) 19 (19) 0 0 (0–84)*** 0
Spain 2 65 61 94 (85–98) 16 (11–22) 60 98 (91–100) 92 (83–98)
Netherlands 3 18 14 78 (52–94) 31 (16–40) 4 29 (8–58) 22 (6–48)
Total 12 725 639 88 (86–90) 17 (8–40) 560 88 (85–90) 77 (74–80)
*1, national ultrasound scan policy; 2, no national scan policy but routine scans carried out; 3, no routine scans.
**95% binomial exact conﬁdence intervals.
***One-sided 97.5 conﬁdence limit.
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mination causes controversy. The laws regarding TOPFA vary
in their gestation limit in the different countries. This study
shows that having a legal limit of less than 28 weeks of gesta-
tion for TOPFA does not have a major impact on termination
rates for Down’s syndrome or NTDs. This implies that a well-
organised screening system should be able to ensure that most
women are given choices before the fetus becomes viable.
A strength of this study is that it provides information on
prenatal policies in place in whole countries rather than in
centres of excellence and attempts to relate policies or lack of
policies to prenatal detection rates. However, there are limi-
tations; ﬁrst, because data are only provided from areas cov-
ered by full EUROCAT registries; for some countries (e.g.
Switzerland and Germany), this will only be from a small area,
which is not necessarily representative of the whole country.
Second, although the year 2004 has been chosen for the exis-
tence or not of a country-wide policy, data are from the years
2002–04. For one country (Denmark, where the screening
policy was introduced in 2004), this may underestimate the
impact of a recently introduced policy.
The existence of a national policy or recommendation for
a particular screening test does not necessarily equate with the
delivery of the offer of such screening to all women in all areas
because of lack of resources, of information provided to
women within the time frame for making an informed deci-
sion,lackofuptake or late booking.11,12 The uptakeand impact
of different programmes will depend on social and cultural
factors as well as on the availability of different resources and
laws regarding TOPFA. The absence of a national screening
policy may reﬂect a considered decision that is itself ‘a policy’.
In this paper, we have concentrated on the two anomalies
(Down’s syndrome and NTDs) for which screening methods
were initially developed. The existence of screening has led to
difﬁcult ‘grey areas’ in terms of what types of birth defect can
now be prenatally detected and whether termination of preg-
nancy is an appropriate choice, for example Turner syndrome
and facial clefts.13–15 There is some concern about a potentially
negative effect of widespread screening on the perceptions
about individuals born with birth defects and the services that
might be available for their care.13,14 However, prenatal screen-
ing has opened up new possibilities to enhance the treatment
and survival of liveborn children with birth defects.16,17
The situation regarding screening policies is not a static
one. Some countries will have already updated their policies
to achieve higher detection and lower false-positive rates.
New developments in noninvasive prenatal testing based
on fetal DNA in maternal blood are becoming a realistic
prospect for the future.18,19 We can expect that prenatal
screening policy will continue to be dynamic and that vari-
ation between countries in Europe will continue to lead to
large but changing differences in prenatal detection and
termination rates.
Conclusion
Prenatal screening policies as well as prenatal diagnosis and
TOPFA rates for Down’s syndrome and NTDs vary widely
across European countries. The majority of Down’s syndrome
and NTD cases are prenatally detected. Having a legal gesta-
tional age limit for TOPFA does not signiﬁcantly alter the
number of pregnancies resulting in TOPFA. National policy
is associated with prenatal detection rate, but organisational
and cultural factors are clearly important.
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